Bio-Rad Laboratories, Inc.Class A
BIOBio-Rad Laboratories, Inc. Class A (BIO) is a global leader in life science research and clinical diagnostics. The company develops, manufactures, and markets a broad range of products, including reagents, instruments, and software, used in scientific research, healthcare, and clinical diagnostics. Bio-Rad is known for its contributions to immunology, genetics, and microbiology, supporting advancements in molecular biology and personalized medicine.
Company News
The global next-generation sequencing (NGS) market is expected to grow from USD 14.25 billion in 2025 to USD 103.24 billion by 2035, at a CAGR of 21.9%. North America currently dominates with 50% market share, while Asia Pacific is the fastest-growing region. Oncology is the leading application segment, and consumables represent the largest produ...
German life sciences company Qiagen is exploring strategic options including a potential sale, with renewed takeover interest from multiple U.S.-based strategic buyers. The company has engaged advisers as its supervisory board evaluates preliminary approaches. CEO Thierry Bernard's announced departure is seen as removing a key obstacle to a deal....
The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.
The global custom antibody market is projected to grow from USD 608.75 million in 2025 to USD 1,297.65 million by 2033, at a CAGR of 9.98%. Growth is driven by increasing demand for precision medicine, targeted therapies, advancements in antibody engineering, and rising investments in biopharmaceutical R&D. However, high development costs and tec...
The global autism spectrum disorder diagnostics market is projected to grow from $27.38 billion in 2024 to $43.36 billion by 2034, with a CAGR of 4.7%. Key growth drivers include increasing healthcare expenditure, R&D investments, and government initiatives. The autistic disorder segment will dominate at 52.82% market share, while early intervent...
